购物车
您的购物车当前为空
GLP-1R/GIPR agonist-1 sodium 是 GLP-1R/GIPR agonist-1 的钠盐形式,作为胰高血糖素样肽-1 受体 (GLP-1R, EC50 为 0.57 nM) 和葡萄糖依赖性胰岛素释放肽受体 (GIPR, EC50 为 0.75 nM) 的双重激动剂,它能通过模拟内源性激素GLP-1和GIP的作用来降低血糖,增强胰岛素分泌并抑制胰高血糖素分泌。此化合物可用于糖尿病、肥胖症及非酒精性脂肪性肝炎 (NASH) 等代谢疾病的研究。
GLP-1R/GIPR agonist-1 sodium 是 GLP-1R/GIPR agonist-1 的钠盐形式,作为胰高血糖素样肽-1 受体 (GLP-1R, EC50 为 0.57 nM) 和葡萄糖依赖性胰岛素释放肽受体 (GIPR, EC50 为 0.75 nM) 的双重激动剂,它能通过模拟内源性激素GLP-1和GIP的作用来降低血糖,增强胰岛素分泌并抑制胰高血糖素分泌。此化合物可用于糖尿病、肥胖症及非酒精性脂肪性肝炎 (NASH) 等代谢疾病的研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 待询 | |
| 50 mg | 待询 | 待询 |
| 产品描述 | GLP-1R/GIPR agonist-1 sodium is the sodium salt form of GLP-1R/GIPR agonist-1. It acts as a dual agonist for the glucagon-like peptide-1 receptor (GLP-1R, EC50 = 0.57 nM) and the glucose-dependent insulinotropic polypeptide receptor (GIPR, EC50 = 0.75 nM). GLP-1R/GIPR agonist-1 sodium lowers blood glucose by mimicking the effects of endogenous hormones GLP-1 and GIP, enhancing insulin secretion, and inhibiting glucagon secretion. This compound is applicable in research on metabolic disorders such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH). |
| 分子式 | C220H334N55O69.xNa |
| Sequence | His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-{Aib}-Leu-Asp-Lys-Arg-Ala-Ala-Lys(AEEA-AEEA-gammaGlu-C18 diacid)-Asp-Phe-Val-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Sequence Short | {Aib}-QGTFTSDYSK-{Aib}-LDKRAA-K(AEEA-AEEA-gammaGlu-C18 diacid)-DFVEWLKNGGPSSGAPPPS |
| 存储 |
对于不同动物的给药剂量换算,您也可以参考 更多